IMB Dx, Inc.

IMB Dx, Inc. provides a liquid biopsy platform in South Korea. Its AlphaLiquid Platform offers circulating-tumor DNA-based precision diagnostics across various stages of cancer for patients, survivors, and individuals. Products include AlphaLiquid HRR for targeted therapy diagnostics using liquid biopsy profiling, and AlphaLiquid 100, a test that detects biomarkers across 118 cancer-related genes from a single blood test. The company also offers CancerDetect, a liquid biopsy platform for early detection of cancer recurrence after surgery, and CancerFind, a blood-based test for early detection of various cancers. IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.